Short answer · Medically reviewed summary · Last updated: 2026-04-07
The estimated prevalence of Premenstrual Dysphoric Disorder (PMDD) is approximately 3% to 8% of women of reproductive age worldwide, though these figures are subject to significant variation based on diagnostic stringency. Prevalence and Diagnostic Challenges While often classified as a common condition rather than a "rare" disease in terms of raw numbers, Premenstrual Dysphoric Disorder is frequently underdiagnosed or misdiagnosed as generalized anxiety or depressive disorders. Data regarding the annual incidence of Premenstrual Dysphoric Disorder remains limited, as many individuals do not seek clinical evaluation until symptoms have persisted for years.
4 people with Premenstrual Dysphoric Disorder have shared their first-person experience on this question at DiseaseMaps.
What is the prevalence of Premenstrual Dysphoric Disorder?
Prevalence of Premenstrual Dysphoric Disorder: how many people are affected worldwide, differences by sex and region, with sources.
The estimated prevalence of Premenstrual Dysphoric Disorder (PMDD) is approximately 3% to 8% of women of reproductive age worldwide, though these figures are subject to significant variation based on diagnostic stringency.
Prevalence and Diagnostic Challenges
While often classified as a common condition rather than a "rare" disease in terms of raw numbers, Premenstrual Dysphoric Disorder is frequently underdiagnosed or misdiagnosed as generalized anxiety or depressive disorders. Data regarding the annual incidence of Premenstrual Dysphoric Disorder remains limited, as many individuals do not seek clinical evaluation until symptoms have persisted for years. The condition is exclusively diagnosed in individuals with a menstrual cycle, as it is fundamentally linked to the luteal phase of the cycle and the body's sensitivity to hormonal fluctuations.
Demographics and Onset
Premenstrual Dysphoric Disorder typically manifests after menarche, with the average age of onset often occurring in the late 20s or early 30s, though it can emerge earlier. Research has not identified significant ethnic or geographic variations in the prevalence of Premenstrual Dysphoric Disorder, suggesting it is a global phenomenon affecting diverse populations. Because the diagnostic criteria require prospective symptom tracking over at least two consecutive cycles, many individuals remain outside of formal medical databases.
Real-World Perspectives
Clinical statistics often fail to capture the lived experience of those suffering from these severe emotional and physical disturbances. The DiseaseMaps.org community, which currently includes 618 members sharing their experiences with Premenstrual Dysphoric Disorder, provides a vital, complementary perspective to clinical data. This real-world evidence highlights the significant burden of disease and the ongoing challenges patients face in accessing timely, effective interventions. As we continue to map the experiences of our community, we gain deeper insight into the true impact of this condition beyond what is recorded in traditional epidemiological studies.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Orphanet: The portal for rare diseases and orphan drugs
- International Association for Premenstrual Disorders (IAPMD)
Posted Jul 24, 2017 by Limerencia 2070
Posted Sep 10, 2017 by son678 2000
Posted Oct 22, 2017 by Deanna 2550
Surveys indicate that PMS is among the most common health problems reported by reproductive-age women. Current estimates of the prevalence of clinically significant PMS vary from 12.6% to 31% of menstruating women. Epidemiologic studies have identified approximately 20% of reproductive age women as having moderate to severe PMS. The prevalence of PMDD is estimated to affect 5% to 8% of menstruating women. Available data suggest that PMS occurs across cultures at essentially comparable rates.
Morbidity
The morbidity of PMS is due to the severity of symptoms, chronicity, and the resulting emotional distress or impairment in work, relationships, and activities. When emotional distress or impairment in work, relationships, and activities. When assessed by standard measures, the level of impairment of PMS is significantly higher than community norms and is similar to that of major depression. Women with PMS report greatest impairments in personal relationships, compromised work levels, and increased absenteeism from work.
Current clinical evidence suggests that PMS tends to be a chronic illness with little spontaneous recovery. Symptoms that improve with medical treatment may worsen quickly after treatment is stopped. Data have indicated that an individual diagnosed with PMDD experiences 3.8 years of disability during her reproductive years.
Risk Factors for Premenstrual Syndrome
Population-based studies have not consistently found a strong association between PMS and standard demographic risk factors such as education, income, employment, marital status, or the number of children. Racial differences have been reported in several studies, with blacks reporting more physical symptoms and a more depressed mood compared to whites. However, other data are conflicting and well-designed studies are needed to definitively identify potential demographic risk factors.
Menstrual cycle characteristics such as cycle length or age at menarche have not been associated with PMS. Oral contraceptive use is also not considered a risk factor for PMS.
Age.
PMS appears to be associated with ovulatory menstrual cycles. Therefore, it may begin at any time after menarche and continue until ovulation ends at menopause. The majority of patients initially seeking treatment for PMS are aged from the mid-20s to late-30s. However, many report that PMS symptoms started a decade earlier. There is evidence that some adolescents experience the same symptoms and the severity levels of older women, but this age group has not yet been represented in clinical trials and data-based evidence is limited.
Stress.
Higher levels of perceived stress and higher "daily hassles" scores have been identified as risk factors for PMS by population-based studies. Traumatic events have been shown to increase the odds of developing PMDD more than 4 times.
Genetics.
Studies of twins have significantly contributed to data related to possible genetic factors in PMS. Kendler and colleagues identified substantial heritability of premenstrual depression and anxiety. These researchers concluded that the genetic risk factors for PMS are not closely related to genetic risk factors for lifetime major depression. No genetic marker or polymorphic profile for PMS has been identified.
Obesity.
A strong association between PMS and a body mass index ≥30 is reported in a recent population-based study. Because previous studies have not focused on the relationship between obesity and PMS, further investigation is needed to confirm these findings.
Overall Health.
Women with other health problems are more likely to have PMS. The presence of just 1 medical or psychological problem has been demonstrated to increase the risk of PMS nearly 2 times.
Depression and Anxiety.
Current mood and anxiety disorders or history of mood or anxiety disorders are common in women with PMS. In a population-based study, nearly 50% of those with PMDD were found to have an anxiety disorder currently or in the past year compared with only 22% without PMDD; approximately 30% with PMDD had a depressive disorder compared with 12% without. In another study of women seeking PMS treatment, 31% had a current mood disorder and 15% a current anxiety disorder.
Posted Aug 9, 2018 by April 3000
